Narrow search
Showing 1 - 10 of 9,382
Cover Image
Patents, data exclusivity, and the development of new drugs
Gäßler, Fabian; Wagner, Stefan - 2019
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data...
Persistent link: https://www.econbiz.de/10012064786
Cover Image
Acquiring R&D projects: who, when, and what? : evidence from antidiabetic drug development
Malek, Jan; Newham, Melissa; Seldeslachts, Jo; … - 2024
This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...
Persistent link: https://www.econbiz.de/10014468769
Cover Image
The Welfare Implications of Patent Protection, Pricing, and Licensing in the Indian Oral Anti-Diabetic Drug Market
Chatterjee, Chirantan - 2015
We evaluate the welfare effects of differential pricing, voluntary licensing, and compulsory licensing in the Indian market for oral anti-diabetic (OAD) drugs. This market includes a new class of molecules called DPP-4 inhibitors, all of which are under patent protection in India. The Indian...
Persistent link: https://www.econbiz.de/10013035611
Cover Image
Guide for the granting of compulsory licenses and government use of pharmaceutical patents
Correa, Carlos María - 2020
Persistent link: https://www.econbiz.de/10012433977
Cover Image
Compulsory licensing as a remedy against excessive pricing of life-saving medicines
Kianzad, Behrang - 2024
The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...
Persistent link: https://www.econbiz.de/10014541546
Cover Image
Is Europe a Laggard in Pharmaceuticals? R&D Joint Ventures, Patent Quality and R&D Productivity
Messinis, George - 2009
‘performed' R&D and ‘extra-mural' R&D, and focuses on R&D productivity and patent quality as key indicators of innovation. The …
Persistent link: https://www.econbiz.de/10013155663
Cover Image
Multinational firms and global innovation
Gumpert, Anna; Manova, Kalina; Rujan, Cristina; … - 2025
This paper provides an integrated analysis of multinational companies’ global production and innovation. We establish … of production, basic innovation and applied innovation, under asymmetric complementarities across these three activities … and quality, and offshore innovation to more countries, including both countries with and without production affiliates …
Persistent link: https://www.econbiz.de/10015326180
Cover Image
Big pharma and monopoly capitalism: a long-term view
Dosi, Giovanni; Marengo, Luigi; Staccioli, Jacopo; … - 2021
an innovation rewarding institution. According to our analysis, pharma patents have constituted legal barriers to protect …
Persistent link: https://www.econbiz.de/10012604733
Cover Image
Vermarktung von Arzneimittelpatenten
Reepmeyer, Gerrit - In: Bittere Arznei : Wirtschaftsethik und Ökonomik der …, (pp. 183-208). 2008
Persistent link: https://www.econbiz.de/10003624150
Cover Image
Lessons from India's implementation of Doha Declaration on TRIPS and Public Health
Batra, Nanditta - 2022
The major bone of contention between the developed and developing countries in the TRIPS negotiations was patents for pharmaceuticals. The US-led developed countries bloc argued in favour of patents for pharmaceuticals amidst opposition from Brazil, India and other countries. Ample evidence,...
Persistent link: https://www.econbiz.de/10013393634